Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.
[BACKGROUND] For patients with ALK-positive metastatic NSCLC, targeted therapy with ALK inhibitors is a recommended first-line treatment.
APA
Shao J, Zhang B, et al. (2026). Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.. BMC cancer, 26(1), 183. https://doi.org/10.1186/s12885-025-15509-7
MLA
Shao J, et al.. "Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.." BMC cancer, vol. 26, no. 1, 2026, pp. 183.
PMID
41491679
Abstract
[BACKGROUND] For patients with ALK-positive metastatic NSCLC, targeted therapy with ALK inhibitors is a recommended first-line treatment. Three generations of ALK-TKIs are now available, varying in efficacy and side effects. It is important to identify patients’ priorities and the benefit-risk trade-offs among potential treatment options.
[METHODS] A discrete choice experiment was conducted in China to elicit the preferences of patients with ALK-positive advanced NSCLC and their family members (both decision-makers for the treatment). Respondents completed multiple hypothetical treatment profiles characterized by 7 attributes. Data were analyzed using mixed logit model. Analysis of minimum acceptable benefit and scenario simulation were conducted. Subgroup analysis was also employed.
[RESULTS] Respondents ( = 115) placed most value on PFS (RI = 58.13%), followed by reduced risk of brain metastasis (RI = 13.04%). Attributes of side effects were considered less critical. When the degree of side effects was altered from mild to moderate, respondents require a minimum increase of 5.34 months in PFS as compensation. Scenario analysis estimated 97.06% of respondents would endorse the new treatment option if the PFS was improved from 36 months to 60 months. Subgroup analysis revealed that the preference patterns of patients and their families are similar. However, respondents’ preferences exhibit heterogeneity for patients with different brain metastasis status, age, and annually household income.
[CONCLUSION] This is currently among the first patient preference DCE study for first-line treatments of ALK-positive mNSCLC. Understanding patients’ preferences can enhance shared decision-making between patients and clinicians, fostering personalized prophylactic treatment plans that may optimize adherence and improve clinical outcomes.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15509-7.
[METHODS] A discrete choice experiment was conducted in China to elicit the preferences of patients with ALK-positive advanced NSCLC and their family members (both decision-makers for the treatment). Respondents completed multiple hypothetical treatment profiles characterized by 7 attributes. Data were analyzed using mixed logit model. Analysis of minimum acceptable benefit and scenario simulation were conducted. Subgroup analysis was also employed.
[RESULTS] Respondents ( = 115) placed most value on PFS (RI = 58.13%), followed by reduced risk of brain metastasis (RI = 13.04%). Attributes of side effects were considered less critical. When the degree of side effects was altered from mild to moderate, respondents require a minimum increase of 5.34 months in PFS as compensation. Scenario analysis estimated 97.06% of respondents would endorse the new treatment option if the PFS was improved from 36 months to 60 months. Subgroup analysis revealed that the preference patterns of patients and their families are similar. However, respondents’ preferences exhibit heterogeneity for patients with different brain metastasis status, age, and annually household income.
[CONCLUSION] This is currently among the first patient preference DCE study for first-line treatments of ALK-positive mNSCLC. Understanding patients’ preferences can enhance shared decision-making between patients and clinicians, fostering personalized prophylactic treatment plans that may optimize adherence and improve clinical outcomes.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15509-7.
같은 제1저자의 인용 많은 논문 (5)
- The role of WNT10B expression in the prognosis of colorectal cancer: A retrospective study based on TCGA database and clinical data.
- The Role of CD4 T Helper Cell Subsets in Hepatocellular Carcinoma: Implications for Tumour Progression and Immunotherapy.
- Structured skin care for a patient with toxic epidermal necrolysis caused by anlotinib: Case report.
- Male infertility and the risk of developing prostate cancer: a bidirectional two-sample Mendelian randomization study.
- Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.